Navigating new DSH ratios and regulatory hurdles in the 340B program

HealthLeaders Media – Thursday, May 28, 2026
By Luke Gale

With post-pandemic Medicaid enrollments on the decline and expected to fall further, revenue cycle leaders warn that successful participation in the 340B drug pricing program will require collaboration and more robust tracking.

Click here to read the entire article.